Greenville pub features special St. Patrick's Day menu
GREENVILLE, N.C. (WNCT) — When it comes to St. Patrick's Day, the City of Greenville does its best to go above and beyond, thanks to local businesses.
There aren't many pubs in town, but Christy's Euro Pub made sure to be a hub for all St. Patty's Day festivities. They featured special menu items like corned beef and cabbage, as well as, Shepard's pie.
'For Christy's, it's very big here. We have a lot of people that come in from out of town, especially to come to Christy's for St Patrick's Day,' Manager Alyssa Gupton said. 'But also, all the community loves to come here Saturday, we actually had our big opening for the St. Patty's Day event. It started from about 11 a.m. and it didn't end until about 1 a.m. that night. So, it was quite a big thing.'
The restaurant had their annual bash over the weekend and also opened their doors at 11 a.m. Monday. Anyone who wants to continue celebrating Monday's holiday can do so until midnight.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Salesforce, Inc. (CRM): A Bull Case Theory
We came across a bullish thesis on Salesforce, Inc. (CRM) on Compounding Your Wealth's Substack. In this article, we will summarize the bulls' thesis on CRM. Salesforce, Inc. (CRM)'s share was trading at $265.37 as of 30th May. CRM's trailing and forward P/E were 41.53 and 23.47 respectively according to Yahoo Finance. Pixabay/Public Domain Salesforce delivered solid Q1 FY2026 results, posting $9.83 billion in revenue, up 11% year-over-year, with subscription and support revenue growing 12% in constant currency. Remaining performance obligations (RPO) reached $60.9 billion, up 13%, reflecting strong demand visibility. Operating cash flow rose 4% to $6.5 billion. Salesforce reaffirmed its full-year guidance, including a 34% non-GAAP operating margin and 9–10% free cash flow growth. Sales Cloud drove 80% of large enterprise deals, with strength in verticals like financial services, healthcare, and retail. Account executive headcount is set to expand by 22% this year. Internationally, growth was robust in Canada, the UK, France, and South Asia, while Japan showed signs of acceleration. The company's AI initiatives are scaling rapidly—AgentForce, a generative AI product, now has over 4,000 paying customers and was featured in 800+ customer deployments, with potential to reach $1 billion in annualized revenue. Data Cloud surpassed $1 billion in ARR and is processing 22 trillion records, up 175% year-over-year. Tableau, MuleSoft, and Slack were also prominent in major deals, as customers increasingly adopt cross-cloud solutions. Salesforce highlighted Slack's evolution into an enterprise AI interface, improving lead routing times dramatically from 20 minutes to 19 seconds. The recent Informatica acquisition aims to enhance data harmonization and accelerate AI capabilities. Salesforce introduced Flex Credits, a usage-based pricing model reflecting early-stage but growing AI consumption. Notable customer wins included PepsiCo, OpenTable, and Takeda. The company raised its FY26 revenue outlook to $41.3 billion, underscoring its transformation toward data, AI, and unified platform-driven growth. Previously, we have covered Salesforce, Inc. (CRM) in April 2025 wherein we summarized a by Quality Equities on Substack. In the article, Salesforce (CRM) was highlighted as a structurally resilient, high-margin software business undervalued due to macroeconomic fears. The article argued that the market was underestimating Salesforce's long-term free cash flow growth, despite strong fundamentals, improving margins, and rising AI-driven innovation. Since our last coverage, the stock is up 13% as of 30th May. Salesforce, Inc. (CRM) is on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 140 hedge fund portfolios held CRM at the end of the first quarter which was 162 in the previous quarter. While we acknowledge the potential of CRM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Upstart Holdings, Inc. (UPST): A Bull Case Theory
We came across a bullish thesis on Upstart Holdings, Inc. (UPST) on Deep Value Retirns' Substack. In this article, we will summarize the bulls' thesis on UPST. Upstart Holdings, Inc. (UPST)'s share was trading at $47.17 as of 30th May. UPST's forward P/E was 28.90 according to Yahoo Finance. A data centre room with cloud technology, illustrating the enterprise application software services. Upstart (UPST) offers compelling upside potential if it can successfully navigate its current challenges and deliver on its growth ambitions. While the company is not yet producing clean free cash flow, management's target to achieve GAAP profitability by the second half of 2025 marks a significant step toward financial sustainability. Upstart's innovative platform and market position give it strong growth prospects, and if it can convert this growth into consistent free cash flow—targeting at least $25 million quarterly—it would validate the long-term investment thesis. Addressing the $700 million net debt and potential equity raise will be critical, but successful deleveraging would strengthen the balance sheet and reduce investor concerns. Achieving these milestones could lead to a substantial re-rating of the stock, with the current $100 per share price target representing a conservative estimate of its upside by mid-2026. For investors who believe in Upstart's technology and market opportunity, the company's path to profitability and improved cash flow generation offers an attractive risk/reward profile, positioning it well to capitalize on its growth potential and reward patient shareholders as it scales sustainably. Previously, we have covered Upstart Holdings, Inc. (UPST) in March 2025 wherein we summarized a by Unconventional Value on Substack. The author highlighted the company's AI-powered lending platform's improved risk models and strong 2024 growth, positioning the company for a recovery and continued expansion if economic conditions improve. Upstart Holdings, Inc. (UPST) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 33 hedge fund portfolios held UPST at the end of the first quarter which was 39 in the previous quarter. While we acknowledge the potential of UPST as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 2, 2025 (the 'Grant Date'), ORIC granted a total of 39,100 non-qualified stock options and 6,500 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2025. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. The stock options have an exercise price equal to the closing price of ORIC's common stock on the Grant Date. Twenty-five percent (25%) of the shares subject to the stock options will vest on the one (1) year anniversary of the Grant Date, with one thirty-sixth (1/36th) of the remaining shares vesting each one-month period thereafter. One-third (1/3rd) of the restricted stock units will vest on each of the first three anniversaries of the Grant Date. The inducement grants are subject to the terms and conditions of the applicable stock option and restricted stock unit agreements and the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan. The inducement grants were approved by ORIC's Compensation Committee of the Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4). About ORIC Pharmaceuticals, Inc. ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. Beyond these two product candidates, ORIC® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to and follow us on X or LinkedIn. Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the vesting of the inducement grants; target indications for ORIC's product candidates; the potential advantages of ORIC's product candidates; and plans underlying ORIC's clinical trials and development. Words such as 'believes,' 'anticipates,' 'plans,' 'expects,' 'intends,' 'will,' 'goal,' 'potential' and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC's ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC's plans to develop and commercialize its product candidates; the potential for clinical trials of ORIC's product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC's operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC's license and collaboration agreements; the potential market for our product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC's ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC's reliance on third parties, including contract manufacturers and contract research organizations; ORIC's ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled 'Risk Factors' in ORIC's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the 'SEC') on May 5, 2025, and ORIC's future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Contact:Dominic Piscitelli, Chief Financial info@ sesión para acceder a tu cartera de valores
